BioSpace News Archive

Brickell Biotech, Inc., a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced that it will report its financial results for the second quarter, ended June 30, 2021.

Vivos Therapeutics, Inc., a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea, announced that the Company has opened TheVivos Institute training center in Denver, Colorado.

I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that its Board of Directors has authorized a new stock repurchase program.

Two new publications in respected medical journals further examine the importance of high-flux dialyzers in maintaining serum albumin levels in hemodialysis patients, Fresenius Medical Care North America (FMCNA) announced today.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company will release second quarter 2021 financial results on Thursday, August 5, 2021, after the close of market.

Palisade Bio, Inc. (Nasdaq: PALI) and co-development partner Newsoara today announced positive topline Phase 2 clinical trial data that LB1148 had a statistically significant (p=0.0008) effect in accelerating the return of bowel function in patients undergoing elective bowel resection surgery.

Melior Pharmaceuticals (Melior) announced that it completed a definitive licensing agreement with Adhera Therapeutics, Inc . (OTCPK: ATRX; Adhera) for Melior’s Parkinson’s disease (PD) candidate, MLR-1019 (armesocarb).

Ocular Therapeutix, Inc. (NASDAQ:OCUL), today announced that it has dosed the first patient in the United States Phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (wet AMD).

Today KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.

Vaxart, Inc. (Nasdaq: VXRT) today announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier.